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Introduction:  The  evidence  on the  effectiveness  of rehabilitation  in lung  cancer  patients  is limited.  Whole
body  vibration  (WBV)  has been  proposed  as an  alternative  to  conventional  resistance  training  (CRT).
Methods:  We  investigated  the effect  of radical  treatment  (RT)  and  of two  rehabilitation  programmes
in  lung  cancer  patients.  The  primary  endpoint  was  a change  in 6-min  walking  distance  (6MWD)  after
rehabilitation.  Patients  were  randomised  after  RT to either  CRT,  WBVT  or standard  follow-up  (CON).
Patients  were  evaluated  before,  after  RT  and  after  12  weeks  of intervention.
Results:  Of  121  included  patients,  70 were  randomised  to  either  CON  (24),  CRT  (24)  or  WBVT  (22).  After
RT, 6MWD  decreased  with  a  mean  of 38 m (95%  CI 22–54)  and  increased  with  a mean  of  95  m  (95% CI
58–132)  in  CRT (p < 0.0001),  37  m  (95%  CI −1–76) in  WBVT  (p = 0.06)  and 1 m  (95%  CI −34–36) in  CONhole body vibration
xercise
(p  =  0.95),  respectively.  Surgical  treatment,  magnitude  of  decrease  in 6MWD  by  RT  and  allocation  to either
CRT or  WBVT  were  prognostic  for reaching  the  minimally  clinically  important  difference  of  54  m  increase
in  6MWD  after  intervention.
Conclusions: RT  of  lung  cancer  signiﬁcantly  impairs  patients’  exercise  capacity.  CRT  signiﬁcantly  improves
and  restores  functional  exercise  capacity,  whereas  WBVT  does  not  fully  substitute  for CRT.. Introduction
A minority of patients with lung cancer receives a treat-
ent with curative intent, consisting of either radical surgery or
eﬁnitive radiotherapy, administered either as single modality or
ombined with platinum-based chemotherapy [11,33,34].
These treatments lead to a decrease in QoL, physical activity
nd enhance their morbidity [10]. Cancer-related fatigue (CRF),
hich is frequently reported by cancer patients, is deﬁned as an
nusual and persistent sense of tiredness, affecting both phys-
cal and mental capacity and is unrelieved by rest [35]. The
nderlying mechanisms are biological (anaemia, pro-inﬂammatory
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ax: +32 9 332 2341.
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cytokines, nutritional and ﬂuid imbalances, muscle wasting), func-
tional (reduced aerobic capacity and decreased activity of daily
living) and psycho-behavioural (sleep disorders, anxiety, depres-
sion, reduced self-efﬁcacy, sleep disorders, distress and difﬁculty
coping). This may lead to a further muscle deconditioning and dis-
use atrophy [35], which in turn may  aggravate the feeling of fatigue
[1].
Oncological rehabilitation has most been extensively studied
in breast cancer patients [28]. The beneﬁcial effects of rehabil-
itation in lung cancer patients, were currently limited to a few
randomised trials. These trials showed that patients with lung can-
cer can improve their exercise capacity, muscle strength and QoL,
however the results were not consistent [2,9,29].
Whole body vibration training (WBVT) has been proposed as
an alternative training modality for resistance training on multi-
gym equipment. WBVT generates vertical sinusoidal vibrations and
elicits in short periods reﬂectory neuromuscular training without
much effort [26]. It is assumed that these vibrations evoke muscle
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ontractions via a tonic vibration reﬂex [32]. In elderly subjects,
BVT improved both aerobic ﬁtness and muscle strength [4].
The present multi-centre trial, acronamed “REINFORCE” (Ran-
omized Exercise trainINg FOr patients with Radically treated
espiratory CancEr), was designed to assess the potential beneﬁcial
ffect of rehabilitation in lung cancer patients. More speciﬁcally,
e wanted to address the following questions: (1) does lung can-
er therapy affect exercise capacity, muscle strength and QoL; (2)
oes a 12-week rehabilitation programme improve 6MWD  (the pri-
ary outcome), maximal exercise capacity, muscle strength and
oL; and (3) are both training methods, WBVT and conventional
esistance training (CRT), equally effective in improving 6MWD  and
ther outcome variables?”
. Materials and methods
Sequential patients with stages I-III lung cancer or mesothe-
ioma, candidate for a treatment with curative intent, were solicited
y their attending physician of four departments of Respiratory
edicine to participate in the present study. Radical treatment
as deﬁned as either radical resection with or without a peri-
perative platinum-based chemo-(radio) therapy, or deﬁnitive
horacic radiotherapy with or without concurrent or sequential
latinum-based induction chemotherapy. Patients were between
8 and 80 years and had a baseline haemoglobin level of at least
 g/dl. Patients with severe cachexia (a decrease of at least 35%
remorbid weight), co-morbidities interfering with exercise train-
ng and contra-indications for WBVT, such as a pacemaker, joint
rostheses or recently introduced osteosynthetic material and
steoporotic fractures were excluded. All patients provided writ-
en informed consent at inclusion. The study was approved by the
thics Committee of each participating hospital.
This open multi-centre trial consisted of a prospective obser-
ational part I, describing the effect of radical treatment and a
andomised part II, analysing the effect of the intervention in those
atients who were radically treated. In part I, patients were evalu-
ted before (M1) and after (M2) radical treatment. M2  was assessed
ithin 8 weeks of resection or within 2 weeks after the end of
he non-surgical treatment. Patients proceeded only to part II, if
heir treatment was considered radical and if their post-treatment
uadriceps force (QF) was either equal or less than 70% of the pre-
icted normal value or showed a decrease of at least 10% from the
aseline value [8]. The randomisation procedure was conducted
irectly after the M2 evaluation.
Patient randomisation was conducted by a blinded, web-based
latform using a minimisation technique with surgery, COPD and
entre as stratiﬁcation variables and with random allocation to
ither a control group (CON), a CRT-group and a WBVT-group.
atients allocated to CON were discouraged to improve their exer-
ise tolerance with professional help. Patients allocated to either
RT and WBVT received 20 min  of aerobic training on the bicy-
le and treadmill at 70% of the respective maximal workload
Wmax) and speed, observed at M2.  Thereafter, CRT-group received
esistance training on multigym equipment starting with three
ets of eight repetitions for each exercise at 50% one-repetition-
aximum (1RM) (Appendix 1). WBVT-group performed exercises
n the vibration platform (FITVIBE, Gymna, Belgium), starting
ith three sets of 30 s for each exercise at 27 Hz. Rehabilitation
tarted within 8 days after randomisation. Patients trained three
imes a week for 12 weeks, whereafter they were re-evaluated
M3). The investigator was unblinded for the intervention and its
valuation.
The Charlson comorbidity index was used to reﬂect comor-
idities [7]. Spirometry, diffusion capacity (DL,CO) and 6MWD
ith continuous oxygen saturation monitoring were measured 89 (2015) 167–174
according to existing guidelines and expressed as percentage pre-
dicted [5,19,23,30]. A change of at least 54 m in 6MWD  was
considered as the minimally clinically important difference (MCID)
[24]. Maximal exercise capacity was  assessed by Wmax and VO2
peak using an incremental symptom-limited cycle ergometer test
and compared with normal values [18]. A change exceeding 10 W
was considered as MCID [25]. QF was assessed using an iso-
metric handheld dynamometer (Microfet; Biometrics, Almere, the
Netherlands) attached to a knee pendicular bank. Extension peak
torque was  evaluated at 60◦ of knee ﬂexion, by performing a 5 s
maximal isometric contraction. The best out of three attempts
was retained. Health-related QoL was  measured by the European
Organisation for Research and Treatment of Cancer Quality of Life
Cancer Questionnaire (EORTC QLQ-C30) and more speciﬁcally the
item physical functioning (PF) [14]. Fatigue was assessed by the
Functional Assessment of Cancer Therapy-Fatigue (FACT-F) [6,37].
Pain and dyspnoea were scored with visual analogue scales (VAS)
[13].
The adherence of the trial was deﬁned as the percentage of
patients completing the intervention. It was calculated as ratio
between the number of patients, who did not drop out and the
total number of patients who were randomised to the active inter-
vention. The attendance was deﬁned as the percentage of attended
sessions of the proposed 36 sessions. At each supervised train-
ing session, the study-intervention-related adverse events were
recorded.
Statistical analysis
Baseline patient characteristics are expressed as medians with
ranges. The effect of radical treatment was analysed in all partic-
ipants completing part I (sample 1). The primary endpoint of the
trial is the change in 6MWD  (m)  in those patients who  proceeded
to part II (sample 2). The null hypothesis is that neither CRT nor
WBVT would result in an increase of at least 54 m in 6MWD, the
proposed MCID [24]. To refute this, a sample size of 57 patients (19
patients in each group) is needed (˛: 0.05; power: 0.80) [3]. Assum-
ing a dropout rate of 50% of patients after part I, 114 participants
had to be included in the study.
The primary endpoint was analysed by performing an intention-
to-treat (ITT)-analysis on sample 2. A per protocol (PP)-analysis
on patients who  completed part II, deﬁned as sample 3, was also
conducted. For the ITT-analysis, missing observations at M3  were
predicted by applying multiple imputations using monotone linear
regression (Proc MI  in SAS 9.3). Linear regression was applied on
50 imputed datasets and the results were combined using SAS Proc
Mianalyse to calculate means with 95% conﬁdence intervals (CI)
[38]. Bonferroni corrections were applied to correct for multiple
pairwise comparisons.
The effect of radical treatment and the combined effect of radical
treatment and intervention, both expressed as changes in exer-
cise capacity, muscle strength and QoL, were analysed with the
paired-T test for differences within, and by one-way ANOVA for
differences in-between groups. These results were expressed as
means with 95%CI (SPSS version 20, Chicago IL). In order to analyse
variables predictive for reaching the MCID in 6MWD,  the alloca-
tion to either CRT or WBVT, together with relevant clinical factors,
were combined in a multiple logistic regression model on sample
3. All comparisons were done with the use of a two-sided  ˛ level of
0.05.
3. Results3.1. Patient population
Between January 2009 and February 2012, 121 consecutive
patients were recruited (Fig. 1). Eighty-six patients completed part
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Fig. 1. CONSORT ﬂow diagram.
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( and constitute sample 1. Before randomisation, 16 additional
atients dropped out. Seventy radically treated patients were ran-
omly assigned to either CON (n = 24), CRT (n = 24) or WBVT (n = 22)
sample 2). Of these patients, 21, 20 and 17, respectively, completed
he intervention (sample 3). Eighty percent of patients completed
he rehabilitation programme. Twelve patients dropped out before
3 because of loss of motivation (n = 6), progression of disease
n = 3), an acute COPD exacerbation (n = 1), an ankle injury unre-
ated to the intervention (n = 1) and worsening of pre-existing
ow back pain, probably not related to the training (n = 1). No
tudy-intervention-related adverse events were observed during
art II.
The baseline clinical features of sample 1 and the three interven-
ion groups were well balanced (Table 1a) with 6MWD  averaging
5% of the predicted value (Table 1b). Signiﬁcant differences in
atient characteristics between the randomised patients (N = 70)
nd the non-randomised patients (N = 51) were not observed,
xcept for median VO2 peak (1.40 L/min (0.8–1.8) vs. 1.24 L/min
0.4–2.4) (Supplementary appendix 1).3.2. Effect of radical treatment (M2 − M1) in sample 1 (N = 86)
The median interval between M1  and M2  was  13 weeks (6–35).
Radical treatment decreased the FEV1 with a mean of 0.4 L (95%
CI 0.3–0.5) (p < 0.001), the DL,CO expressed as a % of the predicted
value decreased with 16% (95% CI 13–20) (p < 0.001) and the 6MWD
with a mean of 38 m (95% CI 22–54) (p < 0.001) (Table 2). Maximal
exercise capacity, QF and QoL were also signiﬁcantly affected.
3.3. Effect of rehabilitation (M3 − M2) in sample 2 (N = 70)
The median interval between M2  and M3 was 13 (5–30), 14
(7–36) and 13 weeks (6–37) for CON, CRT and WBVT, respectively.
Of the proposed 36 sessions, CRT-patients attended a median of
28 (10–36) and WBVT-patients a median of 23 sessions (0–36)
(p = 0.09).
With respect to the primary endpoint, 6MWD  increased with
a mean of 1 m (95% CI −34–36; pp = 0.95) in CON, 95 m (95% CI
58–132; p < 0.0001) in CRT and 37 m (95% CI −1–76; pp = 0.06) in
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Table 1a
Baseline clinical characteristics of sample 1 and the three intervention groups.
PART I CON CRT WBVT
(N  = 86) (N = 24) (N = 24) (N = 22)
Male (N) 64 (74.4) 18 (75.0) 18 (75.0) 15 (68.2)
Median age (years) 63 [29–84] 64 [51–79] 63 [29–76] 60 [38–77]
Median  BMI  (kg/m2) 25 [16–45] 26 [18–35] 26 [17–45] 23 [16–29]
Median  Charlson Comorbidity Index (points) 3 [0–11] 3 [1–7] 3 [0–10] 3 [0–7]
COPD  (N) 36 (41.9) 9 (37.5) 11 (45.8) 9 (40.9)
Smoking status (N)
Never smoker 5 (5.8) 1 (4.2) 2 (8.3) 2 (9.1)
Ex-smokers 48 (55.8) 12 (50) 14 (58.3) 12 (54.5)
Current smoker 33 (38.4) 11 (45.8) 8 (33.3) 8 (36.4)
Pack  years (N) 40 [0–100] 40 [0–80] 40 [0–100] 35 [0–70]
Diagnosis (N)
NSCLC 79 (91.9) 23 (95.8) 22 (91.7) 19 (86.4)
SCLC  4 (4.7) 1 (4.2) 0 3 (13.6)
Mesothelioma 3 (3.5) 0 2 (8.3) 0
Clinical  stage (N)
NSCLC I 44 (52.2) 15 (62.5) 10 (41.6) 12 (54.5)
NSCLC II 16 (18.6) 2 (8.3) 7 (29.2) 4 (18.1)
NSCLC III 17 (22.1) 6 (25) 5 (20.9) 3 (13.6)
NSCLC IV 0 0 0 0
SCLC  limited 4 (4.7) 1 (4.2) 0 3 (13.6)
Mesothelioma I–III 3 (3.5) 0 2 (8.3) 0
Treatment (N)
Any surgery 45 (52.4) 15 (62.5) 10 (41.6) 13 (59)
Surgery  with chemotherapy and/or radiotherapy 21 (24.4) 3 (12.5) 8 (33.4) 5 (22.8)
Lobectomy 50 (58) 15 (83.5) 12 (66.5) 14 (77.7)
Pneumonectomy 16 (16.6) 3 (16.5) 6 (33.5) 4 (22.3)
Radiotherapy 5 (5.8) 1(4.2) 3 (12.5) 0
Radiotherapy and chemotherapy 15 (17.4) 5 (208) 3 (12.5) 4 (18.2)
Table 1b
Baseline assessment of sample 1 and the three intervention groups.
PART I CON CRT WBVT
(N = 86) (N = 24) (N = 24) (N = 22)
Median FEV1 (L) 2.50 [0.79–4.65] 2.40 [1.28–4.18] 2.55 [0.79–4.65] 2.68 [1.39–3.61]
Median  DL,CO (% predicted) 72 [36–154] 81 [43–154] 70 [36–107] 64 [42–101]
Median  6MWD  (m)  510 [232–671] 525 [232–671] 490 [385–625] 522 [375–645]
Median 6MWD  (% predicted) 75 [40–100] 77 [40–100] 73 [60–89] 76 [56–95]
Median  VO2 peak (L/min) 1.4 [0.3–2.5] 1.35 [0.79–2.48] 1.39 [0.69–2.4] 1.34 [0.84–2.23]
Median  Wmax  (W) 99 [36–226] 90 [36–220] 100 [50–226] 100 [56–178]
Median QF (Nm) 96 [28–227] 97 [28–227] 90 [48–186] 102 [50–184]
Median EORTC QLQ-C 30, PF (points) 87 [13–100] 93 [13–100] 87 [20–100] 87 [13–100]
Median  FACT-F (points) 9 [0–42] 7 [4–42] 10 [3–40] 11 [4–29]
Median  VAS pain (points) 0 [0–9] 1 [0–9] 0 [0–7] 1 [0–9]
Median VAS dyspnoea (points) 0 [0–9] 1 [0–9] 1 [0–7] 3 [0–9]
M1:  at inclusion; sample 1: subjects assessed at M1  and M2.
CON: Control; CRT: Conventional Resistance Training; WBVT: Whole Body Vibration Training; FEV1: Forced Expiratory Volume in 1 s; DL,CO: Diffusion Capacity; 6MWD:  6
Minute  Walking Distance; VO2 peak: Peak Oxygen Consumption; Wmax: Maximal Workload; QF: Quadriceps Force; EORTC-C30, PF: European Organisation for Research and
T T-F: F
N ; NSCL
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freatment of Cancer Quality of Life Cancer Questionnaire, Physical Functioning; FAC
:  Number; BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease
re  percentages; Numbers between [ ] are ranges.
BVT (Table 3, Fig. 2). Fifteen (75%) of the CRT, 5 (29%) of the WBVT
nd 5 of the CON (24%) patients reached the MCID for 6MWD.  The
ean change in 6MWD  between CRT and CON was the only signiﬁ-
ant observation (p = 0.002). The PP-analysis showed similar results
Supplementary appendix 2).
The mean change in Wmax  was signiﬁcantly increased in both
RT and WBVT (15 W (95%CI 6–24); pp = 0.002 in both groups).
eventy-four percent of CRT, 63% of WBVT and 50% of CON reached
he MCID for Wmax.
QF signiﬁcantly increased with a mean of 23 Nm (95% CI 10–36)
p = 0.0009) in CRT only.For none of the groups, the score of QLQ-C30 Global and FACT-F
hanged signiﬁcantly. However by combining the active interven-
ion groups (CRT and WBVT) a signiﬁcant increase was  observed
or both QLQ-C30 Global (+7 points (95% CI 0–14), p = 0.04) andunctional Assessment of Cancer Therapy-Scale Fatigue; VAS: Visual Analogue Scale.
C: Non Small Cell Lung Cancer; SCLC: Small Cell Lung Cancer. Numbers between ( )
FACT-F (−3 points (95% CI −5–0), p = 0.04). No differences were
observed between the active intervention groups and the con-
trol group (Table 4). The score for PF and dyspnoea improved
only signiﬁcantly in WBVT (PF: p = 0.04; dyspnoea: p = 0.009). The
scores for pain did not signiﬁcantly change after 12 weeks of
intervention.
3.4. Overall-effect (M3 − M1) and multiple logistic regression in
sample 3 (N = 58)
The 6MWD  did not recover in CON-patients, the mean dif-
ference between M1  and M3 remaining −46 m (95%CI −105–13)
(p = 0.12). The 6MWD  increased with 36 m (95% CI 1–71) in CRT-
patients (p = 0.048) and 16 m (95%CI −20–52) in WBVT-patients
(p = 0.35).
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Table  2
Effect of radical treatment (sample 1).
M1
Mean
(95%CI)
M2
Mean
(95%CI)
M2 − M1
Mean
(95%CI)
P valuea
Mean FEV1 (L) 2.49 [2.31–2.66] 2.09 [1.94–2.24] −0.4 [0.3–0.5] 0 < 0.0001
Mean  DL,CO (% predicted) 75 [70–80] 59 [54–63] −16 [13–20] 0 < 0.0001
Mean  6MWD  (m)  508 [491–525] 471 [451–490] −38 [22–54] 0 < 0.0001
Mean  6MWD  (% predicted) 77 [74–79] 71 [68–74] −5 [3–8] 0 < 0.0001
Mean  VO2 peak (L/min) 1.39 [1.31–1.48] 1.16 [1.07–1.25] −0.6 [0.2–0.3] 0 < 0.0001
Wmax  (W) 105 [96–114] 85 [78–93] −20 [15–25] 0 < 0.0001
Mean  QF (Nm) 102 [93–111] 90 [83–98] −11 [5–18] 0.001
Mean  EORTC QLQ-C 30, PF (points) 83 [79–87] 73 [69–78] −9 [5–14] <0.0001
Mean FACT-F (points) 11 [9–13] 13 [11–15] 2 [0–4] 0.02
Mean  VAS pain (points) 2 [1,2] 3 [2,3] 1 [0–2] 0.05
Mean  VAS dyspnoea (points) 3 [2,3] 3 [3,4] 3 [3,4] 0.03
M1:  at inclusion; M2:  after radical treatment; sample 1: per protocol sample (N = 86), subjects assessed at M1  and M2.
FEV1: Forced Expiratory Volume in 1 s; DL,CO: Diffusion Capacity; 6MWD:  6 Minute Walking Distance; VO2 peak: Peak Oxygen Consumption; Wmax: Maximal Workload;
QF:  Quadriceps Force; EORTC-C30, PF: European Organisation for Research and Treatment of Cancer Quality of Life Cancer Questionnaire, Physical Functioning; FACT-F:
Functional Assessment of Cancer Therapy-Scale Fatigue; VAS: Visual Analogue Scale.
Numbers between [] as 95% CI.
a Paired-T test M2  − M1.
Table 3
Effect of the intervention in 70 randomised patients (sample 2).
CON  (N  =  24)  CRT  (N  = 24)  WBVT  (N  = 22)
M2
Mean
(95%CI)
M3
Mean
(95%CI)
M3 −  M2
Mean
(95%CI)
P valuea M2
Mean
(95%CI)
M3
Mean
(95%CI)
M3 − M2
Mean
(95%CI)
P valuea M2
Mean
(95%CI)
M3
Mean
(95%CI)
M3 −  M2
Mean
(95%CI)
P valuea
6MWD  (m)  476  (434–518)  477  (433–521)  1  (−33–36)  0.95  448  (406–490)  543  (498–589)  95  (58–132)  <0.0001  509  (465–553)  546  (499–594)  37
(−1–76)
0.06
VO2 peak
(L/min)
1.2 (1.0–1.3) 1.3  (1.1–1.4)  0.1  (0–0.2)  0.08  1.1  (1.0–1.3)  1.3 (1.1–1.4)  0.1  (0–0.3)  0.02  1.2  (1.0–1.3)  1.4 (1.2–1.5)  0.2
(0.1–0.3)
0.001
Wmax  (W)  81  (67–96)  88  (73–103)  7  (−3–17)  0.1  86  (72–100)  101  (86–116)  15  (6–24)  0.002  90  (75–104)  105  (89–120)  15  (6–24)  0.002
QF  (Nm)  86  (71–101)  95  (79–111)  9  (−5–23)  0.2  81  (66–96)  104  (88–120)  23  (10–36)  0.0009  97  (81–112)  105  (88–123)  9  (−6–23)  0.2
QLQ-C  30
Global
(points)
63  (51–72)  70  (58–81)  8  (−1–18)  0.07  61  (48–71)  68  (60–72)  8  (−2–17)  0.1  62  (56–72)  69  (60–77)  7  (−4–17)  0.2
QLQ-C  30  PF
(points)
77  (68–85)  78  (69–87)  2  (−6–9)  0.7  70  (61–79)  76  (67–85)  6  (−1–14)  0.09  77  (68–86)  86  (76–95)  8  (0–16)  0.04
FACT-F  (points)  13  (10–−16)  12  (8–15)  −1 (−5–2)  0.4  14  (10–17)  10  (7–14)  −3  (−7–0)  0.08  14  (10–18)  12  (7–16)  −2  (−6–2)  0.3
VAS  pain
(points)
2 (1–3)  3  (1–4)  0  (−1–1)  0.8  3  (2–4)  2  (1–3)  −1  (−2–1)  0.2  3  (1–4)  2  (1–3)  0  (−2–1)  0.6
VAS  dyspnoea
(points)
3 (2–4)  2  (1–3)  −1 (−2–−0)  0.08  3  (2–5)  2  (1–3)  −1  (−2–1)  0.2  4  (3–5)  2  (1–3)  −2  (−3–0)  0.009
M2:  after radical treatment, at randomisation; M3:  at end of the intervention.
CON: Control; CRT: Conventional Resistance Training; WBVT: Whole Body Vibration Training; 6MWD: 6 Minute Walking Distance; VO2 peak: Peak Oxygen Consumption;
Wmax: Maximal Workload; QF: Quadriceps Force; QLQ-C30 PF: European Organisation for Research and Treatment of Cancer Quality of Life Cancer Questionnaire, Physical
Functioning; FACT-F: Functional Assessment of Cancer Therapy-Scale Fatigue; VAS: Visual Analogue Scale.
a Linear regression: M3 − M2.
Table 4
Comparison of the effect of the different interventions in 70 randomised patients (sample 2).
CRT vs. CON WBVT vs. CON CRT vs. WBVT CON vs. CRT and WBVT
M3  − M2
Mean
difference
between
groups (95%CI)
P valuea M3 − M2
Mean
difference
between
groups (95%CI)
P valuea M3  − M2
Mean
difference
between
groups (95%CI)
P valuea M3 − M2
Mean
difference
between
groups (95%CI)
P valuea
6MWD  (m)  94 (43–145) 0.002 36 (−14–87) 0.480 58 (5–111) 0.099 −66 (−21–112) 0.009
VO2 peak (L/min) 0.03
(−0.12–0.19)
1.000 0.08
(−0.08–0.24)
0.903 0.05 (−0.2–0.1) 1.000 −0.06
(−0.19–0.08)
0.815
Wmax  (W)  8 (−5–21) 0.669 8 (−5–21) 0.693 0 (−13–13) 1.000 −8 (−20–3) 0.334
QF  (Nm) 14 (−4–33) 0.390 0 (−20–20) 1.000 15 (−5–34) 0.417 −7 (−24–10) 0.780
QLQ-C30 Global (points) −1 (−14–12) 1.000 −2 (−16–12) 1.000 1 (−13–15) 1.000 1 (−10–12) 1.000
QLQ-C30 PF (points) 5 (−6–15) 1.000 7 (−4–18) 0.693 −2 (−12–8) 1.000 −6 (−15–4) 0.472
FACT-F (points) −2 (−7–3) 1.000 −2 (−6–5) 1.000 −1 (−7–5) 1.000 2 (−3–6) 1.000
VAS  pain (points) −1 (−3–1) 0.873 0 (−2–1) 1.000 −1 (−2–1) 1.000 1 (−1–2) 0.704
VAS  dyspnoea (points) 0 (−2–2) 1.000 −1 (−2–1) 1.000 1 (−1–3) 1.000 0 (−1–2) 1.000
M2:  after radical treatment, at randomisation; M3:  at end of the intervention.
CON: Control; CRT: Conventional Resistance Training; WBVT: Whole Body Vibration Training; 6MWD: 6 Minute Walking Distance; VO2 peak: Peak Oxygen Consumption;
Wmax: Maximal Workload; QF: Quadriceps Force; QLQ-C30 PF: European Organisation for Research and Treatment of Cancer Quality of Life Cancer Questionnaire, Physical
Functioning; FACT-F: Functional Assessment of Cancer Therapy-Scale Fatigue; VAS: Visual Analogue Scale.
a Linear regression: M3 − M2;  Bonferonni corrected P values.
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Fig. 2. 6MWD  at different time points in participants completing the intervention (sample 3). The mean 6MWD  decreased signiﬁcantly in the control (CON) and the
conventional resistance training (CRT) group after radical treatment (M2). After intervention (M3), the 6MWD  increased only signiﬁcantly in the CRT group. The changes
over  time observed in the whole body vibration training (WBVT) group were not signiﬁcant.
Fig. 3. Multiple logistic regression of clinically relevant factors and exercise training on MCID of 6MWD  in sample 3. Surgical treatment, comorbid COPD, the magnitude of
decrease in 6MWD  after radical treatment and the allocation to either CRT or WBVT, were taken in consideration as relevant factors to predict reaching the MCID of at least
54  m in 6MWD  after 12 weeks of intervention. Patients, who underwent surgery, were 10 times more likely to reach this MCID. Patients allocated to either conventional
resistance training (CRT) or whole body vibration training (WBVT) were 6 times more likely to reach the MCID. Patients, who  showed a decrease of more than 50 m in 6MWD
after  radical treatment were 2 times more likely to reach this endpoint.
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Forty percent of COPD patients reached the MCID in 6MWD  vs.
5% of patients without COPD (p = 0.524). Multiple logistic regres-
ion showed that surgical treatment, allocation to either CRT or
BVT and the magnitude of decrease in 6MWD  by the radical treat-
ent, were independently associated with reaching the MCID of
MWD  (Fig. 3).
. Discussion
The present study shows that a 12-week rehabilitation pro-
ramme  in patients with lung cancer signiﬁcantly improves
xercise capacity, muscle strength and QoL, after a previously
igniﬁcant decrease of those variables following treatment with
adical intent. The improvement in 6MWD  was limited to CRT and
as not observed with WBVT. Together with surgery as part of the
adical treatment, the magnitude of the decrease in 6MWD  by the
adical treatment was predictive for reaching the change in 6MWD
f 54 m.
Surgery, chemotherapy, and radiation therapy are known to
ecrease exercise capacity, muscle strength and QoL in lung cancer
atients [15,17,20,27,28,35,36]. The results of the present study are
n line with previously reported data. More importantly, the present
tudy shows that the decrease in 6MWD  after radical treatment
ecovered with CRT and not after usual care. The improvement in
MWD  with CRT largely exceeds the generally accepted threshold
f 54 m reported in COPD patients and ranges between the 40 and
45 m improvement observed in previous studies in lung cancer
atients [3,14]. The impact of rehabilitation on 6MWD  after thora-
otomy for NSCLC was previously investigated in two  randomised
rials. A home-based training programme, initiated after hospital
ischarge, yielded no effect [2], whereas an ambulatory programme
tarting four weeks after surgery resulted in a modest improve-
ent of 35 m [29]. Possibly, residual post-operative pain may  have
nterfered with training intensity in that trial. In the present study,
ehabilitation was not started before the seventh post-operative
eek, at which time post-operative pain had almost completely
isappeared.
The improvement in 6MWD  observed with WBVT (37 m)  was
either clinically nor statistically signiﬁcant. One possible expla-
ation is that the decrease in 6MWD  after radical treatment was
ess pronounced in WBVT than in the other groups, leaving less
oom for improvement. Another possibility is that WBVT induced
n insufﬁcient training effect to improve the 6MWD.  Indeed, to
ncrease walking distance, improvement in both muscle strength
nd muscle power are required, something that is not obtained by
erforming static exercises on a vibrating platform [21]. Whether
onger sets of dynamic training on WBVT are more effective, remain
o be investigated.
The 6MWD  improved more in patients who  underwent a
urgical resection than in non-surgically treated patients. Presum-
bly, the decrease in 6MWD  in surgically treated patients was
ue to immediate effects of immobilisation, pain and ventila-
ory impairment [12], whereas the decrease in functional exercise
apacity caused by chemotherapy and radiotherapy may  have been
ong lasting by attenuating normal cardiovascular and/or skeletal
uscle adaptation to exercise training [17]. Theoretically, the sig-
iﬁcantly longer interval between M1  and M2  in non-surgically
reated patients could have resulted in a more pronounced deteri-
ration of the general condition. However, the 6MWD  at M1  and
2  was not signiﬁcantly different for both subgroups. That patients
ith a low 6MWD  after radical treatment were more likely to reach
he MCID in 6MWD  after the intervention, should be attributed to
he availability of a larger room for improvement, as has previously
een shown in COPD patients [31]. 89 (2015) 167–174 173
A MCID for maximal exercise capacity in radically treated lung
cancer patients has not yet been uniformly deﬁned. Whereas some
claim that an increase of 15% in VO2max  is clinically meaning-
ful, others propose a 10% increase to be clinically relevant in
severe deconditioned and post-operative lung cancer patients [12].
In COPD, a 10-W increase in Wmax  is considered a meaningful
increase [25]. Although this MCID was reached in the majority of
CRT and WBVT-patients, this increase was not statistically signiﬁ-
cant compared to CON-patients, because the present study was not
powered for that outcome.
In rehabilitation, an improvement in QoL is as important as an
increase in physiological outcomes. Conﬂicting results have been
reported on the effect of post-treatment exercise intervention on
QoL in patients with lung cancer [14]. In the present study, physical
functioning, fatigue and dyspnoea all improved with both training
programme, whereas dyspnoea signiﬁcantly decreased with WBVT.
A possible explanation of the beneﬁcial effect of WBVT on dyspnoea
is that it promotes aerobic ﬁtness [4].
An important strength of the REINFORCE-study is its multi-
centre randomised two-tier design with inclusion of consecutive
patients, representative for the average cancer population, man-
aged in a department of respiratory medicine. The structured and
supervised programme ensured not only the safety of the par-
ticipants but also assured monitoring of the training intensity.
Furthermore, 54 m is a tougher MCID-threshold than the proposed
35 m [22]. The included patients were carefully selected in terms
of degree of disability, excluding those who did not need rehabil-
itation, an increasingly important issue in the light of optimal use
of health care resources. Lastly, the results of the ITT-analysis were
not signiﬁcantly different from the PP-analysis.
Weaknesses of this study are its high dropout rate, leading to
an already low sample size. The dropout rate is comparable to the
one observed in our pilot study [3] and reﬂects the heterogeneity of
the impact of the disease and its treatment on ﬁtness, despite thor-
ough staging and a comprehensive radical treatment. The inclusion
of non-surgically treated patients may  have diluted the observed
effect, as surgical patients beneﬁt most from a rehabilitation pro-
gramme. However, by including such patients, the present trial
addresses a group of patients, representative for the larger commu-
nity of lung cancer patients. Another weakness is the inclusion of
three mesothelioma patients whereas the radical treatment intent
in these patients is debatable.
Our data question the use of WBVT as a training modality in a
rehabilitation programme for radically treated lung cancer patients.
Possibly, the present training modality with WBVT did not induce
enough fatigue of the quadriceps muscle.
Additionally, a substantial number of patients did not reach the
MCID for 6MWD.  It remains a challenge to identify patients who do
not respond to a rehabilitative intervention. An analysis of the pre-
dictive value of biomarkers is ongoing. Future studies should also
address the sustainability of the observed improvements. Interest-
ingly, another group is currently investigating the importance of
timing, duration and components of an oncological rehabilitation
programme in postsurgical lung cancer patients [16].
5. Conclusion
This study allows to conclude that a rehabilitation programme
should be proposed to all patients with lung cancer treated with
radical intent, who  exhibit a certain degree of disability related
to the malignancy or its treatment. In these patients, rehabilita-
tion improves and restores their functional and maximal exercise
capacity, muscle strength and QoL to at least baseline levels. A
vibration platform does not fully substitute for conventional multi-
gym equipment.
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